罗欣药业(002793) - 2024 Q4 - 年度业绩

Financial Performance - Total operating revenue for 2024 reached 2.647 billion yuan, an increase of 11.99% compared to the previous year[6] - Net profit attributable to shareholders was -962.49 million yuan, a decrease of 45.58% year-on-year[6] - Net profit attributable to shareholders after deducting non-recurring gains and losses was -771.15 million yuan, down 20.71% from the previous year[6] - Basic earnings per share were -0.89 yuan, a decline of 45.90% compared to the same period last year[5] - Total assets decreased by 15.19% to 4.3399917 billion yuan from the beginning of the period[5] - Shareholders' equity attributable to the parent company dropped by 43.93% to 1.3848898 billion yuan[5] Strategic Initiatives - The company made significant progress in the hospital access work for the innovative drug Tegoprazan, with new indications successfully approved[6] - The company increased marketing investments to enhance brand and product recognition, laying the foundation for future market share expansion[6] Asset Management - The company recognized losses due to adjustments in the fair value of financial liabilities related to the performance of its subsidiary, which fell short of performance commitments[7] - Impairment provisions were made for certain assets based on prudence and market conditions[8]